atorvastatin/aspirin / Generic mfg. - LARVOL DELTA

Patient-Centered Innovations in Ambulatory Care: Developing a Fixed-Dose Tablet to Enhance Adherence for Patients with Chronic Diseases. (PubMed, Drug Dev Ind Pharm) - "ObjectiveTo improve medication adherence in patients with chronic diseases by developing a tablet formulation containing a combination of metformin, atorvastatin, aspirin, and enalapril maleate.SignificanceEffectively managing chronic diseases often requires multiple medications, which can result in low patient adherence and suboptimal therapeutic outcomes...The tablets fulfilled the European Pharmacopoeia 2014 specifications for the tested parameters. The release of all four drugs was fast and a cumulative percent drug release of approximately 50-85% was observed after 15 min.ConclusionsThese findings highlight the significant potential of the combination tablets as a single-dose delivery system, allowing the simultaneous administration of multiple medications for patients with chronic diseases, thereby enabling more effective and streamlined management."

Journal

EFFECT OF ATORVASTATIN PLUS ASPIRIN IN PERIOPERATIVE MYOCARDIAL INJURY IN CANCER PATIENTS: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY - Marcos Ramos (ACC 2025) - "We aimed to determine whether the combination of atorvastatin plus aspirin reduces postoperative adverse outcomes in this population. Cancer patients aged 60 or over or those with two or more cardiovascular risk factors regardless of age who had elevated troponin (hs cTI exceed 99th percentile of the upper reference limit) in the postoperative period of non-cardiac surgery under general anesthesia were randomized 1:1 to receive atorvastatin (80 mg/day) associated with aspirin (100 mg/day - group 1) from the first day postoperative or placebo (group 2) from the first day postperative. These results suggest that PMI in cancer patients impacts the postoperative outcomes. The use of Aspirin plus Atorvastatin showed benefit in the 210 days follow-up and may be of value in this setting. Long-term studies with a larger number of participants are needed to confirm these initial findings."

Clinical • Anesthesia • Cardiovascular • Oncology

Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population. (PubMed, Sci Rep) - "In comparison to the aspirin use alone, the odds ratios with 95% confidence intervals for CVD were 0.43 (0.33, 0.57), 0.69 (0.42, 1.13), 0.44 (0.31, 0.62), 0.34 (0.23, 0.50) and 0.64 (0.49, 0.84) for the combination use of aspirin and atorvastatin, lovastatin, pravastatin, rosuvastatin as well as simvastatin, respectively, in the fully-adjusted model...In conclusion, statins combined with aspirin have a clear advantage over aspirin alone in preventing CVD. In addition, when various sex, age, and fitness levels were considered, as well as with and without diabetes mellitus, the combination usage of aspirin and rosuvastatin had the greatest CVD preventive effects than aspirin coupled with other statins."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

Micellar eco-friendly HPLC method for simultaneous analysis of ternary combination of aspirin, atorvastatin and ramipril: application to content uniformity testing. (PubMed, BMC Chem) - "The suggested technique was employed for the analysis of the three drugs in their prepared tablets maintaining the recommended pharmaceutical ratio without any interference from excipients. The method was further extended to content uniformity testing of RAM. The results were validated according to international council for harmonisation (ICH) guidelines."

Journal • Cardiovascular

Fixed dose combination drugs for cardiovascular disease in a prolonged humanitarian crisis in Lebanon: an implementation study. (PubMed, BMJ Open) - "Implementing an ASCVD secondary prevention FDC improved adherence and CVD risk factors in MSF clinics in Lebanon, with potential for wider implementation by humanitarian actors and host health systems."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Infectious Disease • Novel Coronavirus Disease • Preventive care

Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial). (PubMed, BMC Infect Dis) - "Among patients admitted with mild to moderate COVID-19 infection, additional treatment with aspirin, atorvastatin, or a combination of the two does not prevent clinical deterioration. Trial Registry Number CTRI/2020/07/026791 ( http://ctri.nic.in ; registered on 25/07/2020)."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IL6

Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. (PubMed, Eur Heart J) - P3 | "In people aged >50 years, the polypill appears safe, well tolerated, and might reduce the risk of MCVE. Fatty liver and increased liver enzymes do not affect the safety of the polypill. Liver enzymes may decrease during treatment."

Journal • Cardiovascular • Hepatology • Non-alcoholic Steatohepatitis

A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. (PubMed, Trials) - "Hence, we aim to evaluate the combination of drugs (aspirin, atorvastatin, and nicorandil) with anti-inflammatory, antithrombotic, immunomodulatory, and vasodilator properties as adjuvant therapy in covid- 19...All patients will receive symptomatic treatment with antipyretics, adequate hydration, anticoagulation with low molecular weight heparin, intravenous remdesivir, corticosteroids (intravenous dexamethasone for 5 days or more duration if oxygen requirement increasing or inflammatory markers are raised), and oxygen support...In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol. The study protocol has been reported under the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines."

Clinical • Journal • Acute Coronary Syndrome • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Allergy • Cardiovascular • CNS Disorders • Hematological Disorders • Hepatology • Immune Modulation • Immunology • Infectious Disease • Inflammation • Liver Failure • Musculoskeletal Pain • Myositis • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Systemic Inflammatory Response Syndrome • Thrombocytopenia • Myoglobin

The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study. (PubMed, Arq Bras Cardiol) - "Older individuals were more likely to present with an increased FMD after 6 months of treatment with atorvastatin + aspirin."

Clinical • Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. (PubMed, Front Pharmacol) - " Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients."

Journal • Preclinical • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Ischemic stroke • Metabolic Disorders • CXCL8 • IFNG • IL1R1 • IL6